Finasteride side effects: an honest London risk assessment, not a scare story and not a sales pitch

No hair loss drug generates more heat than finasteride. In one London consulting room a man is told it is 'completely safe, everyone takes it'. In the next, he reads a forum thread that convinces him it will permanently end his sex life. Both consultations have failed him, because neither gave him a number.

This guide gives numbers. Where the numbers are uncertain, it says so. That is the only defensible position on a drug that helps the overwhelming majority of the men who take it and harms a small minority in ways that matter enormously to them.

What the drug does mechanically

Male pattern hair loss is driven by dihydrotestosterone binding androgen receptors in genetically sensitive follicles. Finasteride inhibits the type II isoform of 5-alpha reductase, the enzyme converting testosterone to DHT. At 1mg daily it reduces scalp DHT by around 60% and serum DHT by around 70%, while testosterone rises slightly.

That biochemistry is why it works and why it can cause the side effects it does: DHT has roles beyond the follicle. The therapeutic question is not whether the drug affects a system — it plainly does — but how often that translates into a symptom a person notices.

The side effect numbers, plainly

• Decreased libido: about 1.8% on drug vs 1.3% on placebo in the pivotal one-year trials.
• Erectile dysfunction: about 1.3% vs 0.7%.
• Ejaculatory disorder: about 1.2% vs 0.7%.
• Gynaecomastia (breast tenderness or enlargement): well under 1%, but it is the side effect that most often forces discontinuation.
• Mood change and low mood: reported in post-marketing surveillance; trial-level quantification is poor and the association remains debated.
• In the five-year extension data, the excess over placebo narrowed further as placebo-arm reporting rose with age.

Post-finasteride syndrome: what can honestly be said

A subset of men report sexual, cognitive or mood symptoms that persist for months or years after stopping. This is described as post-finasteride syndrome. There is no agreed diagnostic definition, no biomarker, and no controlled evidence establishing causation or incidence. There are, however, consistent case series and a patient population whose experience is real to them.

The defensible clinical position: it appears rare, it cannot be confidently predicted, and the risk of persistent symptoms is not zero. Men who are anxious about it should probably not take the drug — partly because the anxiety itself worsens both symptom reporting and quality of life, and partly because reasonable alternatives exist.

Reducing your risk sensibly

• Document a baseline: libido, erectile function, mood, and — over 40 — a PSA before starting.
• Start at 1mg daily, not the 5mg prostate dose. There is no hair benefit to the higher dose.
• Consider alternate-day dosing. DHT suppression remains substantial and many London clinicians now use it as a starting schedule.
• Consider topical finasteride 0.25% instead: comparable scalp effect, lower systemic exposure.
• Review at week 6 and month 3. Most problems declare themselves in that window.
• Stop immediately and speak to your prescriber if you develop breast tenderness or a lump.
• Tell every future clinician you take it — especially before any prostate testing.

If you decide against it

There is a full treatment life without finasteride, and London clinics prescribe it daily. Topical minoxidil 5% twice daily is the obvious backbone. Low-dose oral minoxidil adds meaningful density for many men. Microneedling stacks well with either. Ketoconazole 2% shampoo twice weekly has weak but consistent supportive data. LLLT is safe and mildly effective.

The honest caveat: none of these address DHT, so none will match finasteride's ability to slow the underlying process. Expect to hold ground more slowly and to consider surgery earlier. That is a legitimate trade if the risk profile does not suit you.